Cosmo Artificial Intelligence Ltd. received the FDA’s nod for its GI Genius intelligent endoscopy system. The device – the first of its kind, according to the agency – uses artificial intelligence (AI)-based on machine learning to improve the detection of lesions during colonoscopy. It will be rolled out in the U.S. by Medtronic plc, which has exclusive worldwide distribution rights.
In a move that Sanofi SA said will bring it an mRNA-based research platform with applications in oncology, immunology and other diseases, the company has acquired Tidal Therapeutics Inc. for $160 million up front and up to $310 million in milestone payments. The preclinical startup, led by Merrimack Pharmaceuticals Inc. and Torque Therapeutics Inc. co-founder Ulrik Nielsen, is based in Cambridge, Mass.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting 2021, including: Achilles, Advaxis, Affimed, Agenus, Alpine, Amphivena, Amunix, Arch, Arcus, Bayer, Beigene, Bio-Path, Black Diamond, Briacell, C4, Cardiff Oncology, Checkmate, Clovis, Codiak, Crispr, Elevation, Eli Lilly, Essa, F-star, Fusion, Gennao, Genprex, Glycomimetics, Gracell, GT, Hookipa, Hummingbird, Mirati, Instil, Intra-Cellular, Immune-Onc, Immunogen, Iteos, Jubilant, Kezar, Kineta, Kintara.
Cachexia, Teresa Zimmers told the audience at the Annual Meeting of the American Association for Cancer Research (AACR), is "woefully understudied for the outsized impact it has on cancer patients." The condition, which is currently defined as weight loss and muscle wasting, is the direct cause of death in an estimated 25% to 30% of cancer patients. But it is the main subject of only 0.1% of research papers and 0.2% of clinical trials.
RSS
